Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 28;38(34):e263.
doi: 10.3346/jkms.2023.38.e263.

Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study

Si-Ho Kim  1 , Yu Mi Wi  2 , Kyong Ran Peck  3
Affiliations

Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study

Si-Ho Kim et al. J Korean Med Sci. .

Abstract

This study evaluated the clinical outcome of carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia and the clinical effectiveness of tetracyclines-based therapy. In a retrospective cohort study over 5 years period, 108 patients were included in the study. The overall 30-day mortality rate was 71.4%. Pitt's bacteremia score (PBS) (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.22-1.42 per 1-point), colistin-single regimens (aHR, 0.34; 95% CI, 0.17-0.69), and tetracyclines single/tetracyclines-colistin combination regimens (aHR, 0.18; 95% CI, 0.07-0.48) were independently associated with 30-day mortality. Among patients with a PBS < 6, only tetracycline-containing regimens were associated with decreased mortality. Among patients receiving appropriate definite antimicrobials, the tetracyclines-colistin combination (7 of 7, 100%) tended to a higher 30-day survival rate compared to a tetracycline (7 of 12, 57.1%) or colistin single regimen (10 of 22, 41.6%, P = 0.073). Our findings suggest tetracyclines might be effective for treating CRAB infections when combined with colistin.

Keywords: Acinetobacter baumannii; Carbapenem-Resistance; Extensively Drug Resistant; Minocycline; Tetracyclines; Tigecycline.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. The overall 30-day survival rate of each regimen.
TC = tetracyclines.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25(8):951–957. - PubMed
    1. Kim D, Lee H, Choi JS, Croney CM, Park KS, Park HJ, et al. The changes in epidemiology of imipenem-resistant Acinetobacter baumannii bacteremia in a pediatric intensive care unit for 17 years. J Korean Med Sci. 2022;37(24):e196. - PMC - PubMed
    1. Lee H, Yoon EJ, Kim D, Jeong SH, Won EJ, Shin JH, et al. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro Surveill. 2018;23(42):1800047. - PMC - PubMed
    1. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of Ampc β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. - PubMed
    1. Shi H, Lee JS, Park SY, Ko Y, Eom JS. Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist. 2019;12:3925–3934. - PMC - PubMed